Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics

Ting Shi, Ge Gao, Yingli CaoDisease 2016 · DOI

TL;DR

Long noncoding RNAs (lncRNAs) are emerging as promising, non-invasive biomarkers for early cancer detection and prognosis. This review synthesizes current research on lncRNAs' roles in cancer, their detection in body fluids, and their diagnostic potential, highlighting the need for standardization to translate this potential into clinical practice.

What Problem Does This Paper Address?

The paper addresses the critical challenge of early cancer diagnosis. Current tumor biomarkers often lack the necessary specificity and sensitivity, leading to delayed diagnoses, increased mortality, and unnecessary invasive procedures like biopsies. The authors highlight the need for novel, reliable, and non-invasive biomarkers that can accurately detect cancer at its early stages, predict prognosis, and monitor treatment response.

Methods

This paper is a review article, so it doesn't present novel experimental methods. Instead, it synthesizes findings from numerous published studies. The primary methods discussed for detecting and quantifying lncRNAs are:

  • Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR): This is presented as the gold standard for measuring lncRNA expression levels.
  • RNA Sequencing (RNA-seq): Used for comprehensive profiling of lncRNA expression in tissues and cells.
  • Subtractive Hybridization: Employed to identify differentially expressed genes, including lncRNAs, between cancerous and non-cancerous tissues.

The paper also discusses various methods for extracting lncRNAs from different sample types (tissue, cell lines, blood, urine, saliva, gastric juice) and the challenges associated with normalization (e.g., choosing appropriate reference genes) and quantification (relative vs. absolute).

Datasets

Not discussed in the paper. As a review article, it analyzes data from previously published studies rather than presenting new datasets.

Key Insights and Ideas

  • Beyond "Junk DNA": lncRNAs, once dismissed as transcriptional noise, are now recognized as crucial regulators of gene expression involved in fundamental cellular processes, including tumorigenesis.
  • Circulating lncRNAs as Liquid Biopsies: The discovery that lncRNAs are stable and resistant to RNases in body fluids (blood, urine, saliva, etc.) opens the door for non-invasive "liquid biopsies."
  • Diagnostic and Prognostic Potential: Specific lncRNAs (like MALAT1, H19, and HOTAIR) show altered expression patterns in various cancers (lung, prostate, gastric, colorectal, oral squamous cell carcinoma) and are associated with tumor stage, metastasis, and patient prognosis.
  • Mechanisms of Secretion: lncRNAs can be released into circulation via extracellular vesicles (exosomes, microvesicles), high-density lipoproteins (HDL), or protein complexes, suggesting active transport mechanisms.
  • Complementary Biomarkers: While some lncRNAs show high specificity, they may not be sufficient as standalone biomarkers. They are likely to function best as complementary markers alongside existing ones to improve diagnostic accuracy.

Key Results

The paper highlights several lncRNAs with significant diagnostic potential:

  • MALAT1: Found to be upregulated in metastatic lung cancer tissues and associated with poor prognosis. In prostate cancer, it shows promise as a urinary biomarker, improving diagnostic accuracy when combined with PSA.
  • H19: Upregulated in gastric cancer tissues and plasma, demonstrating high diagnostic power for gastric cancer, outperforming conventional markers like CEA and CA199.
  • HOTAIR: Overexpressed in oral squamous cell carcinoma tissues and correlated with tumor progression. In colorectal cancer, its high expression is linked to lymph node metastasis and poor prognosis.
  • LINC00152: Elevated in gastric cancer tissues and plasma, showing potential as a novel blood-based biomarker for GC.

The paper also notes that while some lncRNAs are consistently upregulated in tumor tissues, their expression in body fluids can vary, and sometimes even be downregulated (e.g., MALAT1 in peripheral blood of lung cancer patients), emphasizing the complexity of their role as circulating biomarkers.

Limitations and Future Work

The authors acknowledge several critical limitations and propose future directions:

  • Lack of Standardization: There is no unified protocol for sample collection, lncRNA extraction, selection of endogenous controls for normalization, quality assessment, or quantitative data analysis. This inconsistency hinders the comparability of results across studies.
  • Unclear Biological Functions and Secretion Mechanisms: While lncRNAs are implicated in cancer, their precise biological functions and the detailed mechanisms by which they are secreted into body fluids remain poorly understood.
  • Contradictory Findings: Some studies report conflicting results regarding lncRNA expression levels and their diagnostic performance, underscoring the need for more robust and standardized research.
  • Small Cohort Sizes: Many studies are based on limited sample sizes, which can lead to selection bias and reduce the generalizability of findings.

Future Work Recommendations:

  • Develop Standardized Protocols: Establish uniform guidelines for all steps of lncRNA biomarker analysis, from sample handling to data interpretation.
  • Elucidate Mechanisms: Further research into the biological functions of lncRNAs in cancer and the molecular pathways governing their secretion and transport.
  • Expand Research Cohorts: Conduct large-scale, multi-center studies with diverse patient populations to validate findings and reduce bias.
  • Investigate Combinatorial Biomarkers: Explore the synergistic diagnostic and prognostic value of lncRNAs in combination with existing biomarkers.
  • Clinical Translation: Focus on translating promising lncRNA biomarkers into clinically applicable diagnostic tools.

Summary updated

Abstract

Cancers have a high mortality rate due to lack of suitable specific early diagnosis tumor biomarkers. Emerging evidence is accumulating that lncRNAs (long noncoding RNAs) are involved in tumorigenesis, tumor cells proliferation, invasion, migration, apoptosis, and angiogenesis. Furthermore, extracellular lncRNAs can circulate in body fluids; they can be detected and strongly resist RNases. Many researchers have found that lncRNAs could be good candidates for tumor biomarkers and possessed high specificity, high sensitivity, and noninvasive characteristics. In this review, we summarize the detection methods and possible sources of circulating lncRNAs and outline the biological functions and expression level of the most significant lncRNAs in tissues, cell lines, and body fluids (whole blood, plasma, urine, gastric juice, and saliva) of different kinds of tumors. We evaluate the diagnostic performance of lncRNAs as tumor biomarkers. However, the biological functions and the mechanisms of circulating lncRNAs secretion have not been fully understood. The uniform normalization protocol of sample collection, lncRNAs extraction, endogenous control selection, quality assessment, and quantitative data analysis has not been established. Therefore, we put forward some recommendations that might be investigated in the future if we want to adopt lncRNAs in clinical practice.
BibTeX
@inproceedings{shi2016long,
  author = {Ting Shi and Ge Gao and Yingli Cao},
  title = {{Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics}},
  booktitle = {Disease},
  year = {2016},
  doi = {10.1155/2016/9085195},
}
Figure